Experienced in Melanoma

Dr. Jamie L. Lesnock

Obstetrics and Gynecology | Oncology
UPMC
University Of Pittsburgh Physicians
300 Halket St, 
Pittsburgh, PA 
Experienced in Melanoma
UPMC
University Of Pittsburgh Physicians
300 Halket St, 
Pittsburgh, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jamie Lesnock is an Obstetrics and Gynecologist and an Oncologist in Pittsburgh, Pennsylvania. Dr. Lesnock is rated as an Experienced provider by MediFind in the treatment of Melanoma. Her top areas of expertise are Endometrial Cancer, Ovarian Cancer, Ovarian Carcinosarcoma, Hysterectomy, and Ureteral Reconstruction.

Her clinical research consists of co-authoring 42 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has participated in 1 clinical trial in the study of Melanoma.

Specialties
Obstetrics and Gynecology
Oncology
Licenses
Obstetrics & Gynecology in PA
Hospital Affiliations
Magee Womens Hospital Of Upmc Health System
Upmc Presbyterian Shadyside
Uniontown Hospital
Upmc Altoona
The Washington Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Gateway Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • OTHER MEDICARE PART D
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

UNIVERSITY OF PITTSBURGH PHYSICIANS
300 Halket St, Pittsburgh, PA 15213
Call: 412-641-1000

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 10, 2026
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 02, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Atezolizumab, Bevacizumab, Pegylated liposomal doxorubicin hydrochloride
Study Phase: Phase 2/Phase 3
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: November 25, 2025
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Exemestane, Letrozole, Systemic Chemotherapy
Study Phase: Phase 3
Phase II Randomized Trial of Nivolumab With or Without Ipilimumab in Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Phase II Randomized Trial of Nivolumab With or Without Ipilimumab in Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Enrollment Status: Completed
Publish Date: August 29, 2025
Intervention Type: Biological
Study Phase: Phase 2
Evaluation of Physical Function and Quality of Life (QOL) Before and After Non-Radical Surgical Therapy (Extra Fascial Hysterectomy or Cone Biopsy With Pelvic Lymphadenectomy) for Stage IA1 (LVSI+) and IA2-IB1 (≤ 2CM) Cervical Cancer
Evaluation of Physical Function and Quality of Life (QOL) Before and After Non-Radical Surgical Therapy (Extra Fascial Hysterectomy or Cone Biopsy With Pelvic Lymphadenectomy) for Stage IA1 (LVSI+) and IA2-IB1 (≤ 2CM) Cervical Cancer
Enrollment Status: Active_not_recruiting
Publish Date: May 03, 2024
Intervention Type: Other, Procedure
Study Phase: Not Applicable
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors
Enrollment Status: Completed
Publish Date: September 01, 2022
Intervention Type: Other
A Phase III Randomized Trial of Pulse Actinomycin-D Versus Multi-day Methotrexate for the Treatment of Low-Risk Gestational Trophoblastic Neoplasia
A Phase III Randomized Trial of Pulse Actinomycin-D Versus Multi-day Methotrexate for the Treatment of Low-Risk Gestational Trophoblastic Neoplasia
Enrollment Status: Completed
Publish Date: August 12, 2022
Intervention Type: Other, Drug, Biological
Study Drugs: Dactinomycin, Leucovorin Calcium, Methotrexate
Study Phase: Phase 3
A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
Enrollment Status: Unknown
Publish Date: September 30, 2021
Intervention Type: Other, Drug
Study Drugs: Carboplatin, Metformin hydrochloride, Paclitaxel
Study Phase: Phase 2/Phase 3
View 8 Less Clinical Trials

41 Total Publications

The Role of Adjuvant Chemotherapy in Endometrial Cancer Following Preoperative Neoadjuvant Chemoradiation Therapy.
The Role of Adjuvant Chemotherapy in Endometrial Cancer Following Preoperative Neoadjuvant Chemoradiation Therapy.
Journal: American journal of clinical oncology
Published: April 23, 2025
View All 41 Publications
Similar Doctors
Elite in Melanoma
Dr. Diwakar Davar
Hematology | Oncology
Elite in Melanoma
Dr. Diwakar Davar
Hematology | Oncology

University Of Pittsburgh Physicians

300 Halket St, 
Pittsburgh, PA 
 (0.1 miles away)
Languages Spoken:
English
See accepted insurances

Diwakar Davar is a Hematologist and an Oncologist in Pittsburgh, Pennsylvania. Dr. Davar is rated as a Distinguished provider by MediFind in the treatment of Melanoma. His top areas of expertise are Melanoma, Merkel Cell Carcinoma, Metastatic Uveal Melanoma, Uveal Melanoma, and Gamma Knife Radiosurgery.

Jason J. Luke
Elite in Melanoma
Dr. Jason J. Luke
Hematology Oncology | Oncology
Elite in Melanoma
Dr. Jason J. Luke
Hematology Oncology | Oncology
5150 Centre Ave, 
Pittsburgh, PA 
 (1.5 miles away)
412-647-2811
Languages Spoken:
English
See accepted insurances

Jason Luke is a Hematologist Oncology specialist and an Oncologist in Pittsburgh, Pennsylvania. Dr. Luke is rated as a Distinguished provider by MediFind in the treatment of Melanoma. His top areas of expertise are Melanoma, Metastatic Uveal Melanoma, Uveal Melanoma, Melanoma of the Eye, and Liver Embolization.

Elite in Melanoma
Dr. Yana G. Najjar
Hematology | Oncology
Elite in Melanoma
Dr. Yana G. Najjar
Hematology | Oncology

University Of Pittsburgh Physicians

300 Halket St, 
Pittsburgh, PA 
 (0.1 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Yana Najjar is a Hematologist and an Oncologist in Pittsburgh, Pennsylvania. Dr. Najjar is rated as a Distinguished provider by MediFind in the treatment of Melanoma. Her top areas of expertise are Melanoma, Metastatic Uveal Melanoma, Melanoma of the Eye, Renal Cell Carcinoma (RCC), and Gamma Knife Radiosurgery.

VIEW MORE MELANOMA DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Lesnock's expertise for a condition
ConditionClose
  • Elite
  • Endometrial Cancer
    Dr. Lesnock is
    Elite
    . Learn about Endometrial Cancer.
    See more Endometrial Cancer experts
  • Distinguished
  • Ovarian Cancer
    Dr. Lesnock is
    Distinguished
    . Learn about Ovarian Cancer.
    See more Ovarian Cancer experts
  • Ovarian Carcinosarcoma
    Dr. Lesnock is
    Distinguished
    . Learn about Ovarian Carcinosarcoma.
    See more Ovarian Carcinosarcoma experts
  • Sertoli-Leydig Cell Tumor
    Dr. Lesnock is
    Distinguished
    . Learn about Sertoli-Leydig Cell Tumor.
    See more Sertoli-Leydig Cell Tumor experts
  • Vulvar Cancer
    Dr. Lesnock is
    Distinguished
    . Learn about Vulvar Cancer.
    See more Vulvar Cancer experts
  • Advanced
  • Cervical Cancer
    Dr. Lesnock is
    Advanced
    . Learn about Cervical Cancer.
    See more Cervical Cancer experts
  • Endometrial Stromal Sarcoma
    Dr. Lesnock is
    Advanced
    . Learn about Endometrial Stromal Sarcoma.
    See more Endometrial Stromal Sarcoma experts
  • Hysterectomy
    Dr. Lesnock is
    Advanced
    . Learn about Hysterectomy.
    See more Hysterectomy experts
  • Lump in the Abdomen
    Dr. Lesnock is
    Advanced
    . Learn about Lump in the Abdomen.
    See more Lump in the Abdomen experts
  • Malignant Mixed Mullerian Tumor
    Dr. Lesnock is
    Advanced
    . Learn about Malignant Mixed Mullerian Tumor.
    See more Malignant Mixed Mullerian Tumor experts
  • Testicular Yolk Sac Tumor
    Dr. Lesnock is
    Advanced
    . Learn about Testicular Yolk Sac Tumor.
    See more Testicular Yolk Sac Tumor experts
View All 7 Advanced Conditions
  • Experienced
  • Adenomyosis
    Dr. Lesnock is
    Experienced
    . Learn about Adenomyosis.
    See more Adenomyosis experts
  • Adult Soft Tissue Sarcoma
    Dr. Lesnock is
    Experienced
    . Learn about Adult Soft Tissue Sarcoma.
    See more Adult Soft Tissue Sarcoma experts
  • Alveolar Soft Part Sarcoma
    Dr. Lesnock is
    Experienced
    . Learn about Alveolar Soft Part Sarcoma.
    See more Alveolar Soft Part Sarcoma experts
  • Anal Cancer
    Dr. Lesnock is
    Experienced
    . Learn about Anal Cancer.
    See more Anal Cancer experts
  • Angiomyoma
    Dr. Lesnock is
    Experienced
    . Learn about Angiomyoma.
    See more Angiomyoma experts
  • Bone Tumor
    Dr. Lesnock is
    Experienced
    . Learn about Bone Tumor.
    See more Bone Tumor experts
View All 45 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved

    Request an Appointment

    If you are experiencing a medical emergency, call 9-1-1.

    MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

    Patient Details

    This information is for the patient who will be seen at the appointment.

      Close

      Returning patient? Use your address on file with the provider.

      Insurance Details

      Please provide information of the primary insurance holder as the practice may require this information to schedule.

      Insurance Provider *
      Insurance ProviderClose

      Appointments Details

      Let’s get more information about your appointment.

              0 / 1000
              0 / 1000
              By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.